BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
Number Cited Articles
1
Setareh Mobasheri, Nazanin Irani, Abbas Akhavan Sepahi, Fatemeh Sakhaee, Fatemeh Rahimi Jamnani, Farzam Vaziri, Seyed Davar Siadat, Abolfazl Fateh. Evaluation of TRIM5 and TRIM22 polymorphisms on treatment responses in Iranian patients with chronic hepatitis C virus infectionGene 2018; 676: 95 doi: 10.1016/j.gene.2018.07.023
2
B. Dominguez-Molina, K. Machmach, C. Perales, L. Tarancon-Diez, I. Gallego, J. L. Sheldon, M. Leal, E. Domingo, E. Ruiz-Mateos, Bryan R. G. Williams. Toll-Like Receptor 7 (TLR-7) and TLR-9 Agonists Improve Hepatitis C Virus Replication and Infectivity Inhibition by Plasmacytoid Dendritic CellsJournal of Virology 2018; 92(23) doi: 10.1128/JVI.01219-18
3
Stanislas Pol, Sylvie Lagaye. The remarkable history of the hepatitis C virusMicrobes and Infection 2019; 21(5-6): 263 doi: 10.1016/j.micinf.2019.06.008
4
Johan Noble, Thomas Jouve, Paolo Malvezzi, Lionel Rostaing. Renal complications of liver diseasesExpert Review of Gastroenterology & Hepatology 2018; 12(11): 1135 doi: 10.1080/17474124.2018.1530984
5
K. Ghazal, O. Morales, C. Barjon, G. Dahlqvist, L. Aoudjehane, L. Ouaguia, N. Delhem, F. Conti. Early high levels of regulatory T cells and T helper 1 may predict the progression of recurrent hepatitis C after liver transplantationClinics and Research in Hepatology and Gastroenterology 2019; 43(3): 273 doi: 10.1016/j.clinre.2018.10.005
6
Hui Tian, Zhenkun He. miR-215 Enhances HCV Replication by Targeting TRIM22 and Inactivating NF-κB SignalingYonsei Medical Journal 2018; 59(4): 511 doi: 10.3349/ymj.2018.59.4.511
7
Masoud Behzadifar, Hasan Abolghasem Gorji, Aziz Rezapour, Nicola Luigi Bragazzi. The hepatitis C infection in Iran: a policy analysis of agenda-setting using Kingdon’s multiple streams frameworkHealth Research Policy and Systems 2019; 17(1) doi: 10.1186/s12961-019-0436-z
8
Marta M Gaglia, Karl Munger. More than just oncogenes: mechanisms of tumorigenesis by human virusesCurrent Opinion in Virology 2018; 32: 48 doi: 10.1016/j.coviro.2018.09.003
9
Jia-Horng Kao, Chun-Yen Lin, Wan-Long Chuang, Yao-Yun Cheng, Jui-Yu Hu, Wen-Kai Liang, Peter Friebe, Stuart Palmer, Chin-Shiou Huang. Clinical evaluation of IntelliPlexTM HCV genotyping kit for hepatitis C virus genotypingDiagnostic Microbiology and Infectious Disease 2019; 94(4): 344 doi: 10.1016/j.diagmicrobio.2019.02.020
10
Gema Lledó, Laura Benítez-Gutiérrez, Ana Arias, Silvia Requena, Valentín Cuervas-Mons, Carmen de Mendoza. Benefits of hepatitis C cure with antivirals: why test and treat?Future Microbiology 2019; 14(5): 425 doi: 10.2217/fmb-2019-0041
11
Stanislas Pol, Sylvie Lagaye. The remarkable history of the hepatitis C virusGenes & Immunity 2019; 20(5): 436 doi: 10.1038/s41435-019-0066-z
12
Anne Olbrich, Hedda Wardemann, Stephan Böhm, Karen Rother, Che C Colpitts, Florian Wrensch, Thomas F Baumert, Thomas Berg, Julia Benckert. Repertoire and Neutralizing Activity of Antibodies Against Hepatitis C Virus E2 Peptide in Patients With Spontaneous Resolution of Hepatitis CThe Journal of Infectious Diseases 2019; 220(7): 1209 doi: 10.1093/infdis/jiz274
13
Ahmed S. Abdel‐Moneim. Occult hepatitis C infections: time to change the defined groupsMicrobiology and Immunology 2019; 63(11): 474 doi: 10.1111/1348-0421.12737
14
Sara Abouelasrar Salama, Muriel Lavie, Mieke De Buck, Jo Van Damme, Sofie Struyf. Cytokines and serum amyloid A in the pathogenesis of hepatitis C virus infectionCytokine & Growth Factor Reviews 2019;  doi: 10.1016/j.cytogfr.2019.10.006
15
Antoni Sicras Mainar, Ruth Navarro Artieda, Ignacio Hernández, Ramón Morillo. Prevalencia de las potenciales interacciones medicamentosas entre los antivirales de acción directa pangenotípicos y la medicación concomitante asociada a los pacientes con infección del virus de la hepatitis C crónica en EspañaGastroenterología y Hepatología 2019; 42(8): 465 doi: 10.1016/j.gastrohep.2019.03.014
16
Maja Ružić, Rinaldo Pellicano, Milotka Fabri, Francesco Luzza, Luigi Boccuto, Snežana Brkić, Ludovico Abenavoli. Hepatitis C virus-induced hepatocellular carcinoma: a narrative reviewPanminerva Medica 2018; 60(4) doi: 10.23736/S0031-0808.18.03472-9
17
Noha H. Habashy, Marwa M. Abu-Serie. Major royal-jelly protein 2 and its isoform X1 are two novel safe inhibitors for hepatitis C and B viral entry and replicationInternational Journal of Biological Macromolecules 2019; 141: 1072 doi: 10.1016/j.ijbiomac.2019.09.080
18
Antoni Sicras Mainar, Ruth Navarro Artieda, Ignacio Hernández, Ramón Morillo. Prevalence of the potential drug–drug interactions between pangenotypic direct-acting antivirals and the concomitant medications associated with patients with chronic hepatitis C virus infection in SpainGastroenterología y Hepatología (English Edition) 2019; 42(8): 465 doi: 10.1016/j.gastre.2019.09.001